Rx Extended-Release Guaifenesin Must Exit Market By November, FDA Says
This article was originally published in The Tan Sheet
Executive Summary
Single-ingredient, extended-release prescription guaifenesin products must be removed from the market by the end of November if they have not been approved by FDA, the agency states in Feb. 25 letters to 66 marketers and distributors of the drugs